Weight is rarely just one thing. The patients walking into Ascend for medical weight loss have usually tried six different approaches by the time they sit down with us - calorie counting, intermittent fasting, group programs, gym memberships, sometimes prescription stimulants from somewhere on the internet. None of it stuck, or it stuck and the body fought back. The medications now available - GLP-1 receptor agonists like semaglutide and tirzepatide - are a real tool for the right patient. Not a miracle, not a shortcut. A tool with side effects, costs, and a follow-up requirement that's longer than most people expect when they start.
What is a GLP-1, exactly?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a gut hormone the body normally releases in response to food. The medications slow gastric emptying, reduce appetite signals, and improve insulin response. Semaglutide is the active ingredient in Ozempic (FDA-approved for type 2 diabetes) and Wegovy (FDA-approved for chronic weight management). Tirzepatide - which acts on both GLP-1 and GIP receptors - is the active ingredient in Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The brand name reflects the FDA-approved indication; the molecule is the same. See FDA prescribing information for semaglutide (Wegovy) and tirzepatide (Zepbound) via FDA Drugs@FDA.
For chronic weight management, the FDA-approved indications generally include adults with a BMI of 30 or greater, or BMI 27 or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Those criteria exist because the trials that earned approval enrolled patients who met them. The medications work best as one component of a structured program - alongside nutrition, sleep, activity, and ongoing medical management. They aren't a substitute for that work; they make that work substantially more effective for the right patients. Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002 (STEP 1, semaglutide). Jastreboff AM et al. N Engl J Med. 2022;387(3):205-216 (SURMOUNT-1, tirzepatide).
Who GLP-1 weight loss is for - and who it isn't
Patients we typically work with on GLP-1 weight management:
- Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone
- Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease
- Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined
- Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team
GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders. Pregnancy is also a contraindication. We screen for these before any prescription decision. Patients who are otherwise eligible but pregnant, planning pregnancy, or breastfeeding need an alternative approach - we'll discuss that. See FDA boxed warning on thyroid C-cell tumors observed in rodent studies, included in the prescribing information for GLP-1 receptor agonists.
How GLP-1 weight loss works at Ascend
Step one: a real workup
Your first visit is roughly 45 minutes. We cover weight history (when did the trajectory change, what's been tried, what worked and didn't), lifestyle (sleep, activity, eating patterns, stress, medication list), and a focused exam. Then we order labs:
- HbA1c and fasting glucose - to identify prediabetes or type 2 diabetes
- Comprehensive metabolic panel - kidney and liver function
- Lipid panel - cardiovascular risk picture
- TSH - thyroid disease can drive weight changes and is often missed
- Additional markers based on history (insulin, vitamin D, B12, iron studies as indicated)
We also screen for sleep apnea, mood disorders, and medication-related weight effects (some psychiatric and antidiabetic medications drive weight gain that's worth identifying before adding another medication on top).
Step two: the conversation
If labs and history support GLP-1 candidacy, we walk through options. Branded vs. compounded. Semaglutide vs. tirzepatide. What insurance covers, what it doesn't, and what the actual self-pay numbers look like. We talk about the side-effect profile honestly - the first eight weeks are typically the hardest, the GI side effects are real, and titration matters. We talk about what the medication does and doesn't do: it reduces appetite signals, but it doesn't substitute for protein intake, sleep, or activity. The patients who do best are the ones who use the medication as a tool, not the whole program.
Step three: ongoing monitoring
GLP-1 dosing is titrated upward over weeks to months, starting low. We follow you closely in the early months - tolerability, side effects, weight trajectory, labs. We re-check HbA1c, lipids, and basic metabolic panel periodically. We adjust dose based on response and tolerance. After the initial titration phase, follow-up settles into roughly quarterly visits with periodic labs, depending on your case. Long-term: GLP-1 medications work as long as you take them. Discontinuation typically leads to weight regain unless lifestyle factors have substantially shifted in the meantime, which is why we work on those alongside the medication, not after.
Conditions and situations we treat in medical weight loss
Medical weight loss work overlaps significantly with chronic disease management. The full scope at Ascend includes:
- Obesity and overweight with comorbidities - full workup, GLP-1 candidacy assessment, lifestyle integration
- Type 2 diabetes with weight management goals - GLP-1 medications often address both indications simultaneously
- Hypertension tied to weight - coordinated medication review and lifestyle work
- Dyslipidemia and metabolic syndrome - lipids often improve markedly with weight loss
- Prediabetes - HbA1c 5.7-6.4% range, where intervention can prevent progression
- Fatty liver disease (MASLD) - weight loss is the primary intervention; coordinated workup if indicated
- Insulin resistance with normal HbA1c - full metabolic workup, lifestyle prioritization
- Preventive care screenings - weight management is part of cardiovascular risk reduction, cancer screening pacing, and overall preventive medicine
- Post-bariatric weight regain - coordinated with your surgical team, when appropriate
Our providers
Dr. Jason Saylor, DO is a board-certified osteopathic family medicine physician with 17 years of clinical experience and serves as Ascend's Chief Medical Officer. His clinical scope explicitly includes weight loss management, chronic disease management (diabetes, hypertension, hyperlipidemia, thyroid disease), and preventive medicine - the full picture that medical weight loss work requires. Dr. Saylor sees weight loss patients at our Wesley Chapel and Tampa offices and via Florida-statewide telehealth.
For patients whose weight is intertwined with mental health - binge eating patterns, mood-related eating, medication-related weight gain from psychiatric drugs - our team coordinates with our psychiatric program and our talk therapy team. Integrated care matters here because the prescribers can actually adjust meds together rather than working at cross-purposes.
Insurance & cost
GLP-1 coverage depends heavily on the medication, the indication, and your specific plan. Type 2 diabetes diagnoses generally have better coverage. Coverage for chronic weight management without diabetes is plan-specific and often requires prior authorization with documented BMI, weight-related comorbidities, and sometimes prior treatment failures. Some plans don't cover weight management indications at all.
For self-pay: Self-pay rates depend on the type of visit, whether the program includes medication bundling, and any labs ordered. Our medical billing team will confirm exact pricing when you call (813) 670-3331.
Branded medications (Wegovy, Zepbound) have one cost structure; compounded options have another. Both have FDA considerations worth understanding before deciding. We discuss the actual numbers, your specific plan, and what a realistic monthly cost looks like before any prescription decision. Patients sometimes assume the medication will be unaffordable, sometimes assume it will be cheap; reality is plan-by-plan.